ATE465257T1 - Agonisten für den rezeptor des hepatozyten- wachstumsfaktors und deren anwendungen - Google Patents

Agonisten für den rezeptor des hepatozyten- wachstumsfaktors und deren anwendungen

Info

Publication number
ATE465257T1
ATE465257T1 AT97931275T AT97931275T ATE465257T1 AT E465257 T1 ATE465257 T1 AT E465257T1 AT 97931275 T AT97931275 T AT 97931275T AT 97931275 T AT97931275 T AT 97931275T AT E465257 T1 ATE465257 T1 AT E465257T1
Authority
AT
Austria
Prior art keywords
receptor agonists
growth factor
hepatocyte growth
applications
factor receptor
Prior art date
Application number
AT97931275T
Other languages
English (en)
Inventor
Kenneth Hillan
Ralph Schwall
Kelly Tabor
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE465257T1 publication Critical patent/ATE465257T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT97931275T 1996-07-03 1997-06-20 Agonisten für den rezeptor des hepatozyten- wachstumsfaktors und deren anwendungen ATE465257T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2121596P 1996-07-03 1996-07-03
PCT/US1997/010688 WO1998000543A1 (en) 1996-07-03 1997-06-20 Hepatocyte growth factor receptor agonists and uses thereof

Publications (1)

Publication Number Publication Date
ATE465257T1 true ATE465257T1 (de) 2010-05-15

Family

ID=21803007

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97931275T ATE465257T1 (de) 1996-07-03 1997-06-20 Agonisten für den rezeptor des hepatozyten- wachstumsfaktors und deren anwendungen

Country Status (11)

Country Link
US (1) US6099841A (de)
EP (1) EP0922102B1 (de)
JP (1) JP2000515735A (de)
AT (1) ATE465257T1 (de)
AU (1) AU729029B2 (de)
CA (1) CA2258153C (de)
DE (1) DE69739856D1 (de)
DK (1) DK0922102T3 (de)
IL (1) IL127558A0 (de)
WO (1) WO1998000543A1 (de)
ZA (1) ZA975851B (de)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
WO1999037684A1 (en) * 1998-01-26 1999-07-29 Genentech, Inc. Antibodies to death receptor 4 (dr4) and uses thereof
AU6092900A (en) * 1999-07-14 2001-02-05 Board Of Trustees Of The Leland Stanford Junior University Animals comprising human hepatocellular tissue
JP3877148B2 (ja) * 1999-10-29 2007-02-07 アンジェスＭｇ株式会社 糖尿病性虚血性疾患遺伝子治療
US20080241835A1 (en) * 1999-11-01 2008-10-02 Genentech, Inc. Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby, and methods of using the same
AU2001277854B2 (en) * 2000-06-29 2007-03-01 North Shore-Long Island Jewish Health System Modulators of cellular proliferation and angiogenesis, methods for use and identification thereof
AU2002357388A1 (en) * 2001-12-27 2003-07-24 The United States Of America, As Represented By The Department Of Veterans Affairs Monoclonal antibody imaging and therapy of tumors that express met and bind hepatocyte growth factor
EP2075256A2 (de) 2002-01-14 2009-07-01 William Herman Gezielte Liganden
US9701754B1 (en) 2002-10-23 2017-07-11 City Of Hope Covalent disulfide-linked diabodies and uses thereof
WO2004072117A2 (en) * 2003-02-13 2004-08-26 Pharmacia Corporation Antibodies to c-met for the treatment of cancers
WO2004093892A2 (en) * 2003-04-16 2004-11-04 Genentech, Inc. Stanniocalcin-1, variant or antagonists thereof for selective modulation of vascularization
US20040208876A1 (en) * 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
ITMI20031127A1 (it) * 2003-06-05 2004-12-06 Uni Degli Studi Del Piemont E Orientale Am Anticorpi anti-hgf-r e loro uso
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
CA2545603A1 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto
WO2005108424A1 (en) * 2004-05-06 2005-11-17 Genentech, Inc. Crystal structure of the complex of hepatocyte growth factor bata chain with met receptor and methods of use
US20060003931A1 (en) * 2004-05-06 2006-01-05 Genentech, Inc. Crystal structure of the hepatocyte growth factor and methods of use
JP2008516629A (ja) * 2004-10-20 2008-05-22 ペアス インスティテュート アーベー 肝細胞増殖因子（ｈｇｆ）の生物活性に関する評価
EP2311880A3 (de) 2005-01-05 2011-07-27 Biogen Idec MA Inc. Cripto-bindende Moleküle
US7696170B2 (en) * 2005-01-24 2010-04-13 Kringle Pharma Inc. Fibrosis inhibitor for implanted organ
EP1867339A4 (de) * 2005-03-02 2010-05-26 Mitsubishi Tanabe Pharma Corp Antivirales mittel
US20060263808A1 (en) * 2005-03-25 2006-11-23 Genentech, Inc. C-met mutations in lung cancer
SG159547A1 (en) * 2005-03-25 2010-03-30 Genentech Inc Methods and compositions for modulating hyperstabilized c-met
CN101189023B (zh) 2005-03-31 2013-01-30 通用医疗公司 监测和调制hgf/hgfr活性
MX2007015056A (es) * 2005-06-02 2008-03-11 Galaxy Biotech Llc Metodos para el tratamiento de tumores de cerebro con anticuerpos.
US8133867B2 (en) 2006-03-20 2012-03-13 Seikagaku Corporation Method for treating rheumatoid arthritis with an antibody that binds to a hepatocyte growth factor receptor
JP2009531324A (ja) 2006-03-20 2009-09-03 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 癌標的化のための操作された抗前立腺幹細胞抗原（ｐｓｃａ）抗体
AR059922A1 (es) * 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
US20100150863A1 (en) 2006-12-20 2010-06-17 Bayer Pharmaceuticals Corporation Hydroxy methyl phenyl pyrazolyl urea compound useful in treatment of cancer
WO2009032949A2 (en) 2007-09-04 2009-03-12 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
US20110092452A1 (en) * 2008-03-05 2011-04-21 The Regents Of The University Of Michigan Compositions and methods for diagnosing and treating pancreatic cancer
WO2010096486A1 (en) 2009-02-17 2010-08-26 Cornell Research Foundation, Inc. Methods and kits for diagnosis of cancer and prediction of therapeutic value
JP2013511969A (ja) 2009-11-25 2013-04-11 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 確定的内胚葉細胞の肝分化のための方法
EP2506876B1 (de) 2009-12-02 2016-10-12 Imaginab, Inc. J591-minikörper und cys-diakörper zur adressierung des prostataspezifischen membranantigens (psma) und verfahren zu deren verwendung
EP2588107A1 (de) 2010-07-01 2013-05-08 Takeda Pharmaceutical Company Limited Kombination aus einem cmet-hemmer und einem antikörper gegen hgf und/oder cmet
ES2739503T3 (es) 2010-07-09 2020-01-31 Bioverativ Therapeutics Inc Moléculas de cadena simple procesables y polipéptidos producidos usándolas
BR122014027420A2 (pt) 2010-11-03 2019-08-20 Argenx Bvba Anticorpos anti c-met
US9738707B2 (en) 2011-07-15 2017-08-22 Biogen Ma Inc. Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
US9926364B2 (en) 2011-11-03 2018-03-27 Argen-X N.V. Chimeric human-llama antigens and methods of use
LT2802606T (lt) 2012-01-10 2018-10-10 Biogen Ma Inc. Terapinių molekulių transporto per kraujo-smegenų barjerą padidinimas
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
EA037906B1 (ru) 2013-03-15 2021-06-04 Биовератив Терапьютикс Инк. Препараты полипептида фактора ix
JP6426103B2 (ja) * 2013-10-15 2018-11-21 国立大学法人 東京大学 ｃ−Ｍｅｔタンパク質アゴニスト
BR112016021383A2 (pt) 2014-03-24 2017-10-03 Genentech Inc Método para identificar um paciente com câncer que é susceptível ou menos susceptível a responder ao tratamento com um antagonista de cmet, método para identificar um paciente apresentando câncer previamente tratado, método para determinar a expressão do biomarcador hgf, antagonista anti-c-met e seu uso, kit de diagnóstico e seu método de preparo
CN107001471B (zh) 2014-09-16 2022-01-18 西福根有限公司 抗met抗体和组合物
US11761951B2 (en) 2015-02-04 2023-09-19 Bristol-Myers Squibb Company Methods of selecting therapeutic molecules
UY36550A (es) 2015-02-04 2016-08-31 Roche Innovation Ct Copenhagen As Oligómeros antisentido de tau y sus usos
WO2017027325A1 (en) 2015-08-07 2017-02-16 Imaginab, Inc. Antigen binding constructs to target molecules
WO2018014111A1 (en) 2016-06-22 2018-01-25 Harless William Warren Cancer treatment and metastasis inhibition using an anti-cancer stem cell agent in combination with a neul sialidase inhibitor or a cytokine inhibitor after primary cancer treatment
GB201611123D0 (en) * 2016-06-27 2016-08-10 Euremab Srl Anti met antibodiesand uses thereof
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
US11266745B2 (en) 2017-02-08 2022-03-08 Imaginab, Inc. Extension sequences for diabodies
IT201800000535A1 (it) 2018-01-03 2019-07-03 Procedimenti per la cura del cancro.
SG11202108525VA (en) 2019-02-21 2021-09-29 Regeneron Pharma Methods of treating ocular cancer using anti-met antibodies and bispecific antigen binding molecules that bind met
EP4003003A4 (de) * 2019-07-26 2023-07-26 Ambys Medicines, Inc. Verfahren und zusammensetzungen zur herstellung von hepatozyten
CN114340684B (zh) 2019-09-16 2025-09-12 瑞泽恩制药公司 用于免疫pet成像的放射性标记的met结合蛋白
TW202305012A (zh) * 2021-03-22 2023-02-01 日商肽夢想股份有限公司 c-Met 蛋白質結合肽複合物
IL318630A (en) 2022-09-01 2025-03-01 Regeneron Pharma Methods for treating non-small cell lung cancer using mesenchymal-epithelial transition factor (MET) targeting factors

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5648273A (en) * 1989-12-27 1997-07-15 The United States Of America, As Represented By The Department Of Health And Human Services Hepatic growth factor receptor is the MET proto-oncogene
US5362716A (en) * 1989-12-27 1994-11-08 The United States Of America As Represented By The Department Of Health And Human Services Methods for stimulating hematopoietic progenitors using hepatocyte growth factor and lymphokines
JP2750372B2 (ja) * 1990-06-19 1998-05-13 敏一 中村 賢疾患治療剤
US6566098B1 (en) * 1990-09-14 2003-05-20 The United States Of America As Represented By The Department Of Health And Human Services DNA encoding truncated hepatocyte growth factor variants
DK0584125T3 (da) * 1991-05-10 1997-09-08 Pharmacia & Upjohn Spa Afkortede former af hepatocyt vækstfaktor (HGF) receptor
US5227158A (en) * 1991-06-10 1993-07-13 Genentech, Inc. Method of stimulating hepatocyte proliferation by administration of hepatocyte growth factor and gamma-interferon
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
DE69333807T2 (de) * 1992-02-06 2006-02-02 Chiron Corp., Emeryville Marker für krebs und biosynthetisches bindeprotein dafür
US5316921A (en) * 1992-05-18 1994-05-31 Genentech, Inc. Single-chain hepatocyte growth factor variants
US5328837A (en) * 1992-05-18 1994-07-12 Genentech, Inc. Hepatocyte growth factor protease domain variants
CA2134773A1 (en) * 1992-06-04 1993-12-09 Robert J. Debs Methods and compositions for in vivo gene therapy
DE69310525T2 (de) * 1992-09-16 1997-10-02 Genentech Inc Schutz gegen leberschäden mit hgf
WO1994009969A1 (de) 1992-10-28 1994-05-11 Max Born Inst Fuer Nichtlinear Metall/kunststoff-verbundkörper, verfahren zu dessen herstellung und vorrichtung zur ausführung des verfahrens
ATE183513T1 (de) 1993-06-03 1999-09-15 Therapeutic Antibodies Inc Herstellung von antikörperfragmenten
US5464815A (en) * 1993-09-08 1995-11-07 Genentech, Inc. Inhibition of heparin-binding
US5686292A (en) * 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US8200624B2 (en) 2010-07-20 2012-06-12 Sybase, Inc. Membership tracking and data eviction in mobile middleware scenarios

Also Published As

Publication number Publication date
DK0922102T3 (da) 2010-08-16
ZA975851B (en) 1999-01-04
DE69739856D1 (de) 2010-06-02
US6099841A (en) 2000-08-08
WO1998000543A1 (en) 1998-01-08
EP0922102B1 (de) 2010-04-21
JP2000515735A (ja) 2000-11-28
AU729029B2 (en) 2001-01-25
IL127558A0 (en) 1999-10-28
CA2258153C (en) 2004-08-17
CA2258153A1 (en) 1998-01-08
AU3494997A (en) 1998-01-21
EP0922102A1 (de) 1999-06-16

Similar Documents

Publication Publication Date Title
ATE465257T1 (de) Agonisten für den rezeptor des hepatozyten- wachstumsfaktors und deren anwendungen
ATE517125T1 (de) ANTIKÖRPER GEGEN ßDEATH RECEPTOR 4ß (DR4) UND DEREN VERWENDUNGEN
DE60232660D1 (de) Humane dr4-antikörper und deren anwendungen
TR200000927T2 (tr) Prostaglandin agonistleri ve kemik bozukluklarının tedavisi
DK1181319T3 (da) Kimære DR4-antistoffer og anvendelser deraf
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
DE69838147D1 (de) Verbindungen und methoden zur modulierung von occludin-abhängiger gewebepermeabilität
EP1746160A3 (de) Hepatozyt-Wachstumsfaktor-Rezeptor-Antagonisten und deren Anwendung
BR0206985A (pt) Anticorpos modificados e métodos de uso
DK0733109T3 (da) BMP-12, BMP-13 og seneinducerende præparater dermed
TR199901172T2 (xx) Yeni ikame edilmi� pirazol t�revleri.
TR200002773T2 (tr) Alzheimer tedavisi için smilagenin ve anzurogenin-D ve bunların kullanımı.
BR0107691A (pt) Sapogeninas substituìdas e seu uso
ES2177316T3 (es) Anticuerpos humanos antifacotores ix/ixa.
FI972703A0 (fi) Rekombinantti IL-5-antagonisteja, jotka ovat käyttökelpoisia hoidettaessa IL-5:een liittyviä sairauksia
EE200000587A (et) Uued 15-lülilised ketoasaliidid, meetod nende valmistamiseks ning neid sisaldav farmatseutiline kompositsioon kasutamiseks bakternakkuste ravis
MX9101958A (es) Inhibidores de acat de urea de aminosulfonilo
ATE213233T1 (de) Substituierte caprolactame und deren derivate verwendbar zur behandlung der hiv-krankheit
ATE313561T1 (de) Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen
ATE313628T1 (de) Klonierung und expression von haemophilus somnus transferrin-bindenden proteinen
DE60020970D1 (de) Monoklonaler antikörper mit selektiver bindung an vgf und verwendung zur behandlung von vgf-erkrankungen
DE60229624D1 (de) Peroxiredoxin-arzneistoffe zur behandlung einer hiv-1-infektion
ATE299739T1 (de) Neurokinin b vorläufer aus menschlicher plazenta

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties